Please login to the form below

Not currently logged in
Email:
Password:

Sanofi sees profit slide in Q2

Sanofi has recorded a 13 per cent decline in net income for the second quarter of 2011 despite a boost from recently acquired Genzyme

Sanofi has reported a 13 per cent fall in net income to €2.15bn for the second quarter of 2011 following increased generic competition.

The company's total sales grew by 7 per cent to €8.3bn in the second quarter of the year. However, excluding Genzyme, sales fell by 4 per cent, reflecting sales lost to generic competition. Sales in the US rose by 3 per cent, Western European sales increased by 1 per cent and emerging market sales rose by 12 per cent.

The company's generics business recorded sales of €434m in the second quarter, an increase of 18 per cent.

Christopher Viehbacher, CEO, said: "As expected, the second quarter is the most challenging this year, given the level of generic competition. Against this, growth platforms continue to perform well and strong progress has been achieved in the integration of Genzyme and Merial."

The company reported that at as of the end of July, its R&D portfolio comprised 65 new molecular entities projects and vaccines in clinical development of which 17 are in phase III or have been submitted to the health authorities for approval.

28th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics